Startup Professionals Musings

AUGUST 7, 2020

In the short term you need customers to find you at any price, and in the longer term you need revenue, profit, and return loyalty. That keeps people from pushing themselves to develop the kind of new solutions that will permanently change the business for the better, versus short-term band-aids.

Technical Review 124

Technical Review Layoffs Social Media Metrics 124

Xconomy

OCTOBER 7, 2016

military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. —The U.S.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Both Sides of the Table

FEBRUARY 25, 2019

I work hard to create working relationships with my fellow non-management board members in the same way that every investor ultimately works to develop strong working relationships with founders. cash & unallocated stock options) Should we raise capital, from whom, how much and at what price? The founders of a company are fighting.

Startup 269

Startup Venture Capital Layoffs Resource 269

Xconomy

JULY 1, 2016

At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.

Buzzfeed 59

Buzzfeed News Pricing IBM 59

Both Sides of the Table

SEPTEMBER 15, 2010

I’d rather be Roger Ehrenberg with a thesis around data-centric companies and base my investment decisions on the skills I’ve developed in my career. Either downside scenario requires angel deals to be funded further. This is cheaper for them than waiting for big competitors and buying companies at big prices.

Invest 284

Invest Angel Venture Capital Startup 284

Xconomy

JANUARY 25, 2019

After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.

Guide 63

Guide Patents Startup Develop 63